Search
First randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreBlood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
EU funding calls for hematology
Horizon Europe
MSCA Feedback to Policy 2024 (deadline: September 4, 2024)
MSCA International Cooperation 2024 (deadline: September 4, 2024)
MSCA Postdoctoral Fellowship 2024 (deadline: September 11, 2024)
Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer (deadline: September…
EHA congratulates the Spanish Society of Hematology on its 60th anniversary
EHA President, John Gribben and member of the SEHH, María Victoria Mateos
On Thursday, June 20 the Spanish Society of Hematology (SEHH) officially celebrated its 60th anniversary with a commemorative event in Madrid.
EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies
In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.
Read moreThe European Union must deliver funding for research of blood disorders
At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.
Read moreJosé Carreras Award handed out at the 17th Congress of EHA
He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.
Read moreMyelodysplastic Syndromes (MDS)
The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.
Read moreSWG Educational Activities
EHA-SWG SCIENTIFIC MEETING ON INTEGRATED CELL TRACKING IN ONCOHEMATOLOGY: DIAGNOSIS, TARGETED THERAPY AND RESIDUAL DISEASE
November 10-11, 2022 | Bordeaux, France
Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »